These findings are corroborated by the evidence that administration of the A2AR selective agonist ATL-146e reduces intestinal mucosa inflammation by limiting leukocyte infiltration and pro-inflammatory cytokine release in murine experimental models of IBD (Odashima et al., 2005). This evidence concerns the gene ADORA2A and inflammatory bowel disease.